ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now owns 17,595 shares of the company's stock, valued at $320,756.85. The trade was a 21.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
ACADIA Pharmaceuticals Stock Down 2.6 %
Shares of ACADIA Pharmaceuticals stock opened at $17.61 on Friday. ACADIA Pharmaceuticals Inc. has a 12-month low of $14.15 and a 12-month high of $24.27. The stock has a 50 day moving average price of $18.49 and a two-hundred day moving average price of $16.91. The stock has a market capitalization of $2.93 billion, a P/E ratio of 22.58 and a beta of 0.37.
Analyst Ratings Changes
ACAD has been the topic of a number of research reports. Guggenheim downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the company from $23.00 to $20.00 in a report on Friday, January 3rd. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a "hold" rating and a $22.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $24.00.
View Our Latest Report on ACADIA Pharmaceuticals
Institutional Trading of ACADIA Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new position in ACADIA Pharmaceuticals during the 4th quarter worth $40,935,000. SG Americas Securities LLC increased its stake in shares of ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock worth $45,576,000 after purchasing an additional 1,966,607 shares during the period. Norges Bank acquired a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth about $25,555,000. Renaissance Technologies LLC grew its holdings in ACADIA Pharmaceuticals by 204.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock valued at $22,507,000 after buying an additional 823,333 shares during the last quarter. Finally, Two Sigma Advisers LP grew its holdings in ACADIA Pharmaceuticals by 160.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,263,200 shares of the biopharmaceutical company's stock valued at $23,180,000 after buying an additional 778,900 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.
About ACADIA Pharmaceuticals
(
Get Free Report)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
